MedTrace Logo

Ploidy and Stroma in Early Rectal Cancer

NCT03039595 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-06-09

Study results available
· View outcomes & findings →

Summary

Early rectal cancer can be removed by minimally-invasive surgery, and the standard pathological assessment of the removed tumour gives valuable information about how advanced the tumour is. This gives an indication of how likely the cancer is to recur, so doctors and patient can decide on the most appropriate further treatment and follow-up. However there is still much uncertainty in these predictions about recurrence. This study will assess two further pathology tests, ploidy and stroma ratio in the tumour, by correlating the results with outcome. This will determine whether these two tests provide additional value in predicting outcome. If so, clinicians would be better able to advise patients with early rectal cancer about their prognosis and further management.

Conditions

Interventions

OTHER

Ploidy and tumour:stromal ratio measurements

Ploidy and tumour:stromal ratio measurements will be made on specimens of early rectal cancer removed by transanal endoscopic microsurgery (TEM)

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • Oxford University Hospitals NHS Trust

    lead OTHER

Principal Investigators

  • Chris Cunningham, MD · Employee

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-29
Primary Completion
2019-05-31
Completion
2019-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03039595 on ClinicalTrials.gov